Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Terry A Day

Showing results (141-150 of 150) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 150 results.
Current Treatment Options in Oncology|December 31, 2003
Salivary gland neoplasmsTerry A Day, John Deveikis, M Boyd Gillespie, et al.
The Laryngoscope|August 25, 2020
Free Flap Inset Techniques in Salvage Laryngopharyngectomy Repair: Impact on Fistula Formation and FunctionDiane W Chen, Mark A Ellis, Peter Horwich, et al.
Head & Neck|April 19, 2022
Safety of microvascular free tissue transfer reconstruction of the head and neck in the setting of chronic pharmacologic immunosuppressionRay Wang, Peter Horwich, Vlad C Sandulache, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 3, 2006
Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivoCan E Senkal, Suriyan Ponnusamy, Michael J Rossi, et al.
Current Treatment Options in Oncology|January 15, 2003
Oral cancer treatmentTerry A Day, Betsy K Davis, M Boyd Gillespie, et al.
JCO Oncology Practice|August 28, 2020
Barriers to the Delivery of Timely, Guideline-Adherent Adjuvant Therapy Among Patients With Head and Neck CancerEvan M Graboyes, Chanita Hughes Halbert, Hong Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2011
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring responseSahar A Saddoughi, Elizabeth Garrett-Mayer, Uzair Chaudhary, et al.
JCO Oncology Practice|March 10, 2021
Development and Evaluation of a Navigation-Based, Multilevel Intervention to Improve the Delivery of Timely, Guideline-Adherent Adjuvant Therapy for Patients With Head and Neck CancerEvan M Graboyes, Katherine R Sterba, Hong Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2018
Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity TrialTerry A Day, Keisuke Shirai, Paul E O'Brien, et al.
Cell Reports. Medicine|November 10, 2021
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinomaHannah M Knochelmann, Joshua D Horton, Sixue Liu, et al.
Pageof 15

Showing results (141-150 of 150) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 150 results.
Current Treatment Options in Oncology|December 31, 2003
Salivary gland neoplasmsTerry A Day, John Deveikis, M Boyd Gillespie, et al.
The Laryngoscope|August 25, 2020
Free Flap Inset Techniques in Salvage Laryngopharyngectomy Repair: Impact on Fistula Formation and FunctionDiane W Chen, Mark A Ellis, Peter Horwich, et al.
Head & Neck|April 19, 2022
Safety of microvascular free tissue transfer reconstruction of the head and neck in the setting of chronic pharmacologic immunosuppressionRay Wang, Peter Horwich, Vlad C Sandulache, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 3, 2006
Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivoCan E Senkal, Suriyan Ponnusamy, Michael J Rossi, et al.
Current Treatment Options in Oncology|January 15, 2003
Oral cancer treatmentTerry A Day, Betsy K Davis, M Boyd Gillespie, et al.
JCO Oncology Practice|August 28, 2020
Barriers to the Delivery of Timely, Guideline-Adherent Adjuvant Therapy Among Patients With Head and Neck CancerEvan M Graboyes, Chanita Hughes Halbert, Hong Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 28, 2011
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring responseSahar A Saddoughi, Elizabeth Garrett-Mayer, Uzair Chaudhary, et al.
JCO Oncology Practice|March 10, 2021
Development and Evaluation of a Navigation-Based, Multilevel Intervention to Improve the Delivery of Timely, Guideline-Adherent Adjuvant Therapy for Patients With Head and Neck CancerEvan M Graboyes, Katherine R Sterba, Hong Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2018
Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity TrialTerry A Day, Keisuke Shirai, Paul E O'Brien, et al.
Cell Reports. Medicine|November 10, 2021
Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinomaHannah M Knochelmann, Joshua D Horton, Sixue Liu, et al.
Pageof 15